Member Info for Laura2022

"So much more to come "

It's very appealing

Disgusting from the board and allowing Pinnacle to take control

The appointments in August and Sept where exaploned via RNS

· further expansion and diversification of its client base;

· expansion of its consulting business into the adjacent area of pharmaceutical biostatistics services; and

· exploration of opportunities around its personalised oncology software offering.

 

Dr Sargent will join as a key member of the Company's senior leadership team (but not as a board director) and will report directly to Dr Jim Millen. The hiring of Dr Sargent forms part of a strategy to revert to a more traditional board structure where the roles of Executive Chairman and CEO are separated. 

 

Executive Chairman & CEO, Dr Jim Millen, commented:

"I am delighted that Physiomics has been able to attract a candidate of the calibre of Dr Peter Sargent, who joins us with significant experience of building service businesses in the biopharmaceutical sector. Peter will work closely with myself and my senior management team to set and drive forwards the Company's key business priorities and I look forward to him making a significant positive impact."

Long may it continue

From the Nov 17th presentation- ilistened again last night

1 Good to see ithe in depth presentation. (50 minutes) , had an initial listen and a good  slide fron Peter which broken down the 36 project into various sections and that pipeline was £1mln and can be a "top up process" into this pot. The current cash/equiv (+ new £130k grant i) of r £700,000 is good for the foreseeable future and not less than 12-15mths  He said there are 9 of these which are ready to be signed. He re iterated the information from the annual report that they are targeting their best ever revenues (£1.0mln+ ) having already secured about £300k since June 2023 and with Merck back on board in August 2023 whom accounted for 40% of previous revenues (therefore about £300-400k) He expects that Merck will continue be a key client for PYC going forward 

Also stated they would inform the market if these were to be beaten .

If you get time newuncle listen to the VAL interview yesterday on BRR media

From 44th minute onwards she talks about being in regular contact regarding the merger on NASDAQ for VAL201, wrongly or rightly she explained that she couldn't guarantee timing of funds hence prudent for the fund raise , well worth a listen

As for other news I think Brighty or KingH said December is often news fro Merck

What's a C and H please

Thanks for that overview Newuncle

This seems ridiculous to be at £2mln market value again , but then again it seems very quiet on lots of shares this week

Would be great to get a contract or two

Yes, as a relative newcomer I didn't warm at all to all he seemed disinterested bit also conceited

I suspect many won't,for a variety of valid and not so valid reasons, be even taking the time to listen to the actual words .

If people put aside the extreme emotive views and in some cases agendas

Suzy From 44mins onwards deals very well and openly àbout VAL201 amd the timing and nature of fund raise with the NOMAD/AIM rules surrounding timing QND not being willing to "gamble" the whole of the Company on VAL201 money

Clarence

I will listen tonight

Did anyone ask or ir did they cover the Q and A comment about substantial news before the year end ( as mentioned in Sept 2023 Q and A)

N4P pharma had great news today, hopefully we can follow

Yes newincle

It looks like an over reaction and looking out for further updates

Should be news from Merck on the other one we both invest in

I have purchased some qt 0.74 and 0.8p

Wonder what their thoughts are ,seemed very confident of a successful case win

Thanks,I assume just carry on it core business and new products

On 15 December 2023, in the United States District Court for the District of Delaware in the case of CAP-XX vs Maxwell (C.A. No. 19-1733-JLH), the jury has affirmed that CAP-XX patents were invalid and as a result Maxwell does not infringe the nominated CAP-XX patents and Maxwell is not liable to pay CAP-XX damages nor license fees.

That would be nice

Company mentioned an additional Sheffield contract too in the Nov Q and A +one would qssume we might hear from merck and Bicycle

Really interesting article

Thanks